Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05345197 · ClinicalTrials.gov registry record · Phase 2
Emicizumab in Patients With Acquired Hemophilia A
A Phase 2 study of Acquired Hemophilia A, sponsored by University of Washington.
- Active
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
- 16
- Study locations
NCT05345197: Active Phase 2 study of Acquired Hemophilia A, sponsored by University of Washington.
NCT05345197 is a Phase 2 study of Acquired Hemophilia A that is active but no longer recruiting, run by University of Washington. The registered enrollment target is 51 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower). The trial reports 16 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05345197, a Phase 2 study of Acquired Hemophilia A, is active but no longer recruiting, sponsored by University of Washington.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
- 16
- Study locations
Study Summary
This is a phase II multicenter open-label, single-arm prospective study to evaluate the efficacy of prophylactic emicizumab administered on a scheduled basis to prevent bleeds in patients with acquired hemophilia A (AHA).
Primary Outcome
Number of clinically significant bleeds after 12 weeks of study drug (emicizumab)
Conditions Studied
Interventions
- DRUG emicizumab
Study Locations (16)
Pennsylvania
- Penn Blood Disorders Program, Hospital of the University of Pennsylvania - Philadelphia
- Hemophilia Center of Western Pennsylvania - Pittsburgh
California
- UCSD Hemophilia and Thrombosis Treatment Center - San Diego
District of Columbia
- Georgetown University - Washington D.C.
Georgia
- Emory University - Atlanta
Illinois
- Bleeding and Clotting Disorders Institute - Peoria
Indiana
- Indiana Hemophilia and Thrombosis Center, Inc. - Indianapolis
Louisiana
- Tulane University - New Orleans
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2022-08-31 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What the registry record for NCT05345197 still lists
NCT05345197 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Acquired Hemophilia A appearing as the primary indexed condition, and to 1 intervention - of which emicizumab is the first listed.
NCT05345197 lists 16 locations in 15 states (Pennsylvania, California, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT05345197 about?
NCT05345197 is a clinical study titled "Emicizumab in Patients With Acquired Hemophilia A". This is a phase II multicenter open-label, single-arm prospective study to evaluate the efficacy of prophylactic emicizumab administered on a scheduled basis to prevent bleeds in patients with acquired hemophilia A (AHA).
What is the current status of trial NCT05345197?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2022-08-31. Estimated completion is 2026-12.
What conditions does trial NCT05345197 study?
This clinical trial studies the following conditions: Acquired Hemophilia A.
What interventions are being tested in trial NCT05345197?
The interventions under investigation include: emicizumab (DRUG).
Who is sponsoring clinical trial NCT05345197?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05345197 being conducted?
This trial has 16 study locations across California, District of Columbia, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05345197's enrollment target sits among peer trials
51 1190th of 2000 higher than 806 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI